MedPath

A prospective, double-blinded, randomized controlled trial to evaluate the efficacy of intravenous nefopam on postoperative opioid consumption after laparoscopic liver surgery

Phase 4
Active, not recruiting
Conditions
Patients after laparoscopic liver surgery
Nefopam, Laparoscopic liver surgery, Postoperative pain, Opioid consumption
Registration Number
TCTR20230428001
Lead Sponsor
Khon Kaen University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Active, not recruiting
Sex
All
Target Recruitment
104
Inclusion Criteria

1. Age 18-65 years old
2. Patient who undergoing laparoscopic liver surgery
3. ASA classification I-III

Exclusion Criteria

1. Severe systemic medical condition such as poor-controlled hypertension, heart disease, lung disease, renal dysfunction with GFR less than 60, poor-controlled diabetes mellitus, Child-Pugh class B or C, Abnormal liver function test (total bilirubin > 2 mg/dL, INR > 1.7, albumin < 3,5 g/dL, or aspartate or alanine aminotransferase > 2 times of upper limit of normal), neuromuscular disease
2. Chronic pain problem
3. Prescribed analgesic drugs
4. Contraindication to nefopam such as tachyarrhythmia, pregnancy, convulsive disorder, taking monoamine oxidase inhibitors
5. Allergic to study drugs
6. Unable or refusal to use IV PCA
7. Unable to understand and report numeric rating pain score
8. Anesthetic care personnel plan to do neuraxial or trunk blocks

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cumulative morphine consumption in 24 hours At 24 hours postoperatively Data from IV PCA machine
Secondary Outcome Measures
NameTimeMethod
Postoperative pain score At 0, 1, 6, 12, 24, 48 hours postoperatively Numeric rating scale,Incidence of adverse effects During 24 hours postoperatively Dry mouth, profuse sweating, nausea, and vomiting
© Copyright 2025. All Rights Reserved by MedPath